Reference:
1. Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol 2014;171:3604-19.
2. Cardinali DP, Vidal MF, Vigo DE. Agomelatine: its role in the management of major depressive disorder. Clin Med Insights Psychiatry 2012;4:1-23.
3. Valdoxan (agomelatine). Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/valdoxan-epar-product-information_en.pdf
Keywords:
agomelatine, half-life, ยาต้านซึมเศร้า, ค่าครึ่งชีวิต